Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase 1 53Phase 3 32Phase 1/2 11Phase NA 6Phase EARLY_PHASE1 5Phase 4 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 26Other hematologic neoplasm 23Breast 11Myeloid 5Plasma cell 4Classical hematology 3Sarcoma 2Other neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Cyclophosphamide × CNS × Clear all
NCT02066220 2025-12-04

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Universitätsklinikum Hamburg-Eppendorf

Phase 2/3 Active not recruiting
360 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡